Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC
Cancer Science · 2025
DOI: 10.1111/cas.16428 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, 2025. Verfasst von Pengcheng Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital & Nanjing Medical Univ…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Fund for Distinguished Young Scholars of Jiangsu Province grant, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Although epidermal growth factor receptor tyrosine kinase inhibitors ( EGFR ‐TKIs), especially third‐generation TKIs, have significantly improved the progression‐free survival and overall survival of non‐small cell lung cancer (NSCLC) patients with EGFR mutation, TKI resistance is inevitable for most patients. Over the past few years, immune checkpoint inhibitors (ICIs) have significantly improved the survival for EGFR ‐wild type NSCLC patients. However, no significantly improved benefits were observed with ICI monotherapy in EGFR ‐mutated patients. EGFR ‐mutated NSCLC shows more heterogeneity in tumor mutational burden (TMB), programmed cell death‐ligand 1 (PD‐L1), and immune microenvironment characteristics. Whether ICIs are suitable for EGFR ‐mutated NSCLC patients remains to be elucidated. In this review, we summarized clinical trials of ICIs or combined therapy in EGFR ‐mutated NSCLC patients. We further discussed the factors determining the efficacy of ICIs in EGFR ‐mutated NSCLC patients, the mutation subtypes and microenvironment characteristics of potential responders. More importantly, we provided insights into areas worth further investigation in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Resear…
- The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
- Department of Scientific Research, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Key Laboratory of Molecular and Translational Can…
- Jiangsu Biobank of Clinical Resources, Nanjing, China.
- Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
ORCID-Profile: Rong Yin
Förderung
- Natural Science Fund for Distinguished Young Scholars of Jiangsu Province grant
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Zhu, P., Li, Z., Sun, Y., Liu, T., & Yin, R. (2025). Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC. Cancer Science. https://doi.org/10.1111/cas.16428
Vancouver
Zhu P, Li Z, Sun Y, Liu T, Yin R. Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC. Cancer Science. 2025. doi:10.1111/cas.16428
BibTeX
@article{Zhu2025,
author = {Zhu, Pengcheng and Li, Zhitong and Sun, Yuxiang and Liu, Tongyan and Yin, Rong},
title = {Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16428}
}
EUVIMED